ras oncogene product p21 expression and prognosis of human ovarian tumors

Yaginuma, Yuji; Yamashita, Kohki; Kuzumaki, Noboru; Fujita, Masahiro; Shimizu, Tetsuya

doi:10.1016/0090-8258(92)90194-n

Cited by 24 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results partly differ from two previous immunohistochemical studies (Rodenburg et al, 1988;Yaginuma et al, 1992) that found no correlation between p21 levels and clinical outcome but are in agreement with recent work by Katsaros et al (1995), performed by immunoblot analysis. This discrepancy may be due to the different methods employed and the use of different monoclonal antibodies -RAP-5 (Rodenburg et al, 1988) and RAP-28 (Yaginuma et al, 1992) -from the one (Y13-259) used both in our study and in that of Katsaros. RAP-5 binds to proteins of a variety of molecular weights in many different neoplastic and normal cell types, while Y13-259 does not recognize ras-related proteins and is of proven specificity to p21 ras (Robinson et al, 1986).…”

Section: Detection Of Point Mutationscontrasting

confidence: 57%

“…(1997) ras expression is inversely correlated with the expression of the NM-23 protein, which is believed to play an important role in the suppression of metastases (Scambia et al, 1996). Our results partly differ from two previous immunohistochemical studies (Rodenburg et al, 1988;Yaginuma et al, 1992) that found no correlation between p21 levels and clinical outcome but are in agreement with recent work by Katsaros et al (1995), performed by immunoblot analysis. This discrepancy may be due to the different methods employed and the use of different monoclonal antibodies -RAP-5 (Rodenburg et al, 1988) and RAP-28 (Yaginuma et al, 1992) -from the one (Y13-259) used both in our study and in that of Katsaros.…”

Section: Detection Of Point Mutationscontrasting

confidence: 57%

See 1 more Smart Citation

Prognostic significance of ras/p21 alterations in human ovarian cancer

Scambia

Masciullo²,

Panici³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-ras oligonucleotide hybridization in 78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal ovaries. A cut-off value of an integral of absorbance (i.a.) of 2.20, obtained by receiver operating characteristic (ROC) curve, was shown to be the best cut-off for defining p21 positivity. p21 levels were higher in malignant tumours than in benign tumours (median 2.10 i.a. vs median 1.22 i.a.; P= 0.014) and in omental metastases than in primary ovarian carcinomas (median 2.54 i.a. vs median 2.1 i.a.; P= 0.0089). p21 overexpression did not correlate with any of the clinicopathological parameters examined. Follow-up data were available for 63 patients. A significant relationship was shown between p21 positivity and a shorter overall survival (OS) (P < 0.03) and progression-free survival (PFS) (P< 0.03). In multivariate analysis only the presence of ascites, p21 levels and epidermal growth factor receptor status retained an independent prognostic role. K-ras gene mutations were frequently detected in benign and low malignant potential tumours (71.4%), which were mostly mucinous (P= 0.01 52).

show abstract

Section: Detection Of Point Mutationscontrasting

confidence: 57%

Section: Detection Of Point Mutationscontrasting

confidence: 57%

Prognostic significance of ras/p21 alterations in human ovarian cancer

Scambia

Masciullo²,

Panici³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A number of genetic alterations have been observed in ovarian cancer, but little is known about their prognostic role. Cmyc amplification (Baker et al, 1990;Sasano et al, 1992) or Ki-ras mutations (Yaginuma et al, 1992) are involved in a very low percentage of cases. C-erb-B2 gene amplification and/or overexpression has been demonstrated in 20-30% of ovarian malignant tumours (Kacinski et al, 1992;Fajac et al, 1995), but these alterations do not seem to be important in identifying subsets of patients with poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

Buttitta

Marchetti²,

Gadducci³

et al. 1997

Br J Cancer

131

View full text Add to dashboard Cite

show abstract

“…The IGF-II gene may play an important role in the growth of some tumors; in many of these tumors it is high ly expressed compared with normal tissue [7], There are indications that genomic imprinting may play a role in causing a number of diseases, although it has been reported in only a small number of embryonal tumors and lung cancers [8], In gynecologic tumors, there are no reports of genomic imprinting, although genetic altera tions have been identified, such as the activation of onco genes [9][10][11] and inactivation of tumor suppressor genes [12][13][14], This report is, therefore, the first study of genomic imprinting in gynecologic tumors.…”

Section: Introductionmentioning

confidence: 99%

Relaxation of Insulin-Like Growth Factor-ll Gene Imprinting in Human Gynecologic Tumors

Yaginuma¹,

Nishiwaki²,

Kitamura

et al. 1997

Oncology

Self Cite

View full text Add to dashboard Cite

To test for the existence of genomic imprinting in human gynecologic tumors, we analyzed the allelic expression of human insulin-growth factor-II (IGF-II) genes. Genomic imprinting is the parental allele-specific expressions of genes, and recently imprinting of IGF-II gene has demonstrated that parental IGF-II was monoallelically expressed. To study whether IGF-II gene imprinting occurs in human gynecologic tumors, we examined allele-specific expression using an Apal polymorphism in the 3’ untranslated region of IGF-II gene exon 9. We used 19 gynecologic tumor cell lines, and 66 human gynecologic tumors. Four of 19 cell lines (21 %) were informative, and three of these four cell lines (75%) revealed loss of imprinting (LOI). For gynecologic tumors, 24 of 66 were informative (36%), and 5 of the 24 (21%) had LOI. We have reported here that the IGF-II gene is expressed biallelically in some gynecologic tumors. We suggest that LOI of the IGF-II gene is involved in the development of some gynecologic tumors.

show abstract

ras oncogene product p21 expression and prognosis of human ovarian tumors

Cited by 24 publications

References 17 publications

Prognostic significance of ras/p21 alterations in human ovarian cancer

Prognostic significance of ras/p21 alterations in human ovarian cancer

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

Relaxation of Insulin-Like Growth Factor-ll Gene Imprinting in Human Gynecologic Tumors

Contact Info

Product

Resources

About